The Latest
-
Nami Sumida/BioPharma Dive
Deep DiveThe coronavirus vaccine frontrunners are advancing quickly. Here's where they stand
Supply deals inked by the U.S. with most of the leading coronavirus developers, most recently J&J, secure some 700 million vaccines doses.
UPDATED: Aug. 4, 2020 at 7:07 p.m. -
Permission granted by Veradigm
Sponsored by VeradigmAdvancing cardiac care through health information technology
A talk with the American College of Cardiology about how they are working with Health IT to deliver their guidance to the point-of-care.
-
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from https://www.flickr.com/photos/nihgov/49565892277/in/album-72157713108522106/.
India's role in coronavirus vaccine manufacturing grows with new deals
The Serum Institute, one of the world's largest vaccine producers, licensed Novavax's experimental shot, while Wockhardt signed on with the U.K. to help make AstraZeneca's candidate.
-
Courtesy of Bristol-Myers Squibb
Bristol Myers, Pfizer fend off a key challenge to their top-selling heart drug
A district court ruling likely ensures that the companies' blood thinner Eliquis won't face generic competition until at least 2026.
-
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
US to pay $1B to stock up on J&J's coronavirus vaccine
The agreement, which would supply the U.S. with 100 million doses of J&J's experimental shot, is the latest in a string of deals the country has reached with vaccine developers.
-
FDA rejects a peanut allergy treatment, sinking a small biotech's shares
Given the long list of requirements in the FDA's rejection letter, DBV Technologies likely has years of work ahead to win approval of Viaskin Peanut.
-
Amarin
Amarin decides to go it alone in Europe, as uncertainty clouds heart drug's US future
Chief executive John Thero said the company decided against "multiple proposals" for sales partnerships on Vascepa in Europe. Doing so, however, keeps the pressure on Amarin to deliver.
-
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
Big pharma alliance recruits first patients for unusual COVID-19 study
The trial is testing whether drugs from Amgen, Takeda and AbbVie can combat the life-threatening immune overreaction some COVID-19 patients experience.
-
Novartis AG
Novartis says CAR-T cancer therapy works in second lymphoma type
Early results from a trial testing Kymriah in follicular lymphoma were reportedly positive, supporting the pharma's plans to ask for another approval.
-
Lilly to test COVID-19 antibody drug in unorthodox nursing home study
Seeking fast answers in a pandemic, Lilly will use mobile RVs to set up infusion clinics at assisted living facilities, which have become COVID-19 hot spots.
-
Getty Images
Bausch Health to pay $45M to settle US charges over Valeant-era accounting
The agreement comes four years after an accounting scandal led to the unraveling of then-Valeant's image as a new breed of drugmaker.
-
GlaxoSmithKline
US promises $2.1B to Sanofi, GSK in latest coronavirus vaccine deal
The contract is the largest yet from the Trump administration's Operation Warp Speed, although Sanofi and GSK have yet to begin clinical testing of their shot.
-
Getty Images
Pfizer spinoff Cerevel to raise $445M in merger with blank-check company
Deals involving so-called special purpose acquisition companies, or SPACs, have boomed, offering the neuroscience-focused Cerevel an unorthodox, and lucrative, path to go public.
-
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
Vaccine sales driven down by pandemic's effects on doctor visits
Pfizer, Sanofi, GSK and Merck each reported lower vaccine sales as stay-at-home orders kept people from their regular vaccinations.
-
Getty / Edited by BioPharma Dive
Sangamo, Novartis team up to develop genetic medicines for autism, other brain disorders
The deal, which hands Sangamo $75 million upfront, is the second pharma partnership the biotech has signed this year to focus on brain disease drugs.
-
Can Sanofi's top drug carry it through a pandemic?
While Dupixent sales are booming, the French firm's heavy reliance on the drug could leave it exposed if pricing reforms occur in the U.S.
-
Getty Images
Merck nears clinical tests for coronavirus vaccine candidates
Two candidates recently acquired in deals with IAVI and Themis have shown promise in preclinical studies, Merck executives said, and Phase 1 trials will begin later this year.
-
Courtesy of Bristol-Myers Squibb
Bristol Myers resubmits cancer cell therapy, lifting investors' chance at payout
A surprise refusal by the FDA in May to review Bristol Myers' application put at risk a conditional payment promised as part of the pharma's Celgene deal.
-
National Institute of Allergy and Infectious Disease. (2020). "Novel Coronavirus SARS-CoV-2" [Microscope image]. Retrieved from https://www.flickr.com/photos/nihgov/49565158853/.
J&J, beginning first human trial, aims for a 1-shot coronavirus vaccine
Preclinical data published Thursday suggest one dose of J&J's vaccine could protect against coronavirus disease, but that goal has proved difficult for drugmakers so far.
-
National Institute of Allergy and Infectious Diseases. (2020). "Novel coronavirus SARS-CoV-2" [Microscope image]. Retrieved from https://www.flickr.com/photos/nihgov/49565158908/in/album-72157713108522106/.
AstraZeneca signals it won't wait for US data to seek clearance of coronavirus vaccine
The British drugmaker indicated on a conference call that data from trials already underway in the U.K., Brazil and South Africa will be sufficient to ask regulators to approve the vaccine.
-
Courtesy of Roche
A Roche arthritis drug fails in COVID-19, casting doubt on a strained hypothesis
Negative results for Actemra follow setbacks for Kevzara, which works similarly, and further weaken the case that the drugs could help treat severe COVID-19.
-
Permission granted by University of Maryland School of Medicine
BioNTech, Pfizer pick a surprise coronavirus vaccine, follow Moderna into late-stage test
After testing four variations of their vaccine, the companies chose a different version for Phase 3 than the one previously thought to be most advanced.
UPDATED: July 28, 2020 at 11:54 a.m. -
Retrieved from Flickr.
Trump invites high-stakes showdown with big pharma as election looms
Industry officials refused to attend a White House meeting called after Trump announced executive orders meant to revive several drug pricing proposals
UPDATED: July 28, 2020 at 11:22 a.m. -
Permission granted by Gilead Sciences
Europe secures supply of Gilead's COVID-19 drug remdesivir
For about $75 million, the European Commission will secure enough doses of the in-demand drug to treat 30,000 patients.
-
Courtesy of FujiFilm
US taps camera makers for help manufacturing drugs, vaccines
The Trump administration plans to loan Kodak $765 million to produce drug ingredients, one day after enlisting Fujifilm to help make coronavirus vaccines.
-
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from Flickr.
On eve of first big coronavirus vaccine study, trial leaders brace for 'unprecedented' task
Researchers will need millions of volunteers to find the roughly 150,000 required for the five Phase 3 trials expected this year. Here's what lies ahead for them.
